A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110

Exclusion Criteria

• •Female participant of childbearing potential or male participant that is unable or unwilling to use an approved, reliable means of contraception
• •Body mass index (BMI) \> 32 or \< 18.5 kg/m2
• •History or current clinical evidence of hepatic disease
• •Evidence of active infection
• •History of medical condition(s), eg, advance cardiac disease, current or recent malignancy, organ transplantation, or other illness
• •Serology result indicative of any exposure (past or active) to hepatitis C, hepatitis B, or human immunodeficiency virus (HIV)
• •Respiratory or other acute illness within 8 weeks
• •Tobacco use of any kind within 6 months
• •Female participant of childbearing potential or male participant that is unable or unwilling to use an approved, reliable means of contraception
• •BMI \> 32 or \< 18.5 kg/m2 or weight \> 90 kg
• •History of FEV1 \< 35%
• •History or current clinical evidence of advanced hepatic disease and/or pulmonary disease
• •Use of an experimental therapy except KRRO-110 within 6 months or 5 half-lives for the experimental therapy, whichever is greater
• •Tobacco use of any kind within 6 months
• •Use of conventionally dosed AAT augmentation therapy within 5 half-lives
• •Serology result consistent with exposure to HIV, or serology consistent with active hepatitis B or hepatitis C infection